Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83 — VEE C-84  

Venezuelan Equine Encephalomyelitis Clinical Trial

Official title: A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus

Status Active, not recruiting

Clinical Trial Summary

The study is designed to assess the safety and immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI GSD 205, as a booster vaccination.

Clinical Trial Description

Study Objectives: Primary: To assess safety of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI GSD 205, as a booster vaccination as a single dose or a three-dose series, and To assess immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI GSD 205, as a booster vaccination as a single dose or a three-dose series Secondary: To assess incidence of VEE infection in C-84 boosted personnel. ;

Related Conditions & MeSH terms

• Encephalomyelitis
• Encephalomyelitis, Equine
• Encephalomyelitis, Venezuelan Equine
• Venezuelan Equine Encephalomyelitis

• NCT number: NCT00582088
• Study type: Interventional
• Source: U.S. Army Medical Research and Development Command
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 2008
• Completion date: December 2021